1. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one. Issue 1 (November 2016) Authors: Lundqvist, Andreas; van Hoef, Vincent; Zhang, Xiaonan; Wennerberg, Erik; Lorent, Julie; Witt, Kristina; Sanz, Laia; Liang, Shuo; Murray, Shannon; Larsson, Ola; Kiessling, Rolf; Mao, Yumeng; Sidhom, John-William; Bessell, Catherine; Havel, Jonathan; Schneck, Jonathan; Chan, Timothy; Sachsenmeier, ... Journal: Journal for immunotherapy of cancer Issue: Volume 4:Issue 1(2016) Page Start: 1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 342 A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk. (9th November 2020) Authors: Choueiri, Toni; Albiges, Laurence; Powles, Thomas; Mohamed, Nehal; Wang, Fong; Motzer, Robert Journal: Journal for immunotherapy of cancer Issue: Volume 8(2020)Supplement 3 Page Start: A209 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma. Issue 8 (16th October 2018) Authors: Lee, Chung-Han; Motzer, Robert Journal: British journal of cancer Issue: Volume 119:Issue 8(2018) Page Start: 911 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Cytoreductive Nephrectomy and Nephrectomy/Complete Metastasectomy for Metastatic Renal Cancer. (2007) Authors: Russo, Paul; Synder, Mark; Vickers, Andrew; Kondagunta, Varuni; Motzer, Robert Other Names: Clark Peter E. Academic Editor. Journal: TheScientificWorldjournal Issue: Volume 7(2007) Page Start: 768 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study. (May 2018) Authors: Molina, Ana M.; Hutson, Thomas E.; Nosov, Dmitry; Tomczak, Piotr; Lipatov, Oleg; Sternberg, Cora N.; Motzer, Robert; Eisen, Tim Journal: European journal of cancer Issue: Volume 94(2018) Page Start: 87 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Elderly patients with metastatic renal cell carcinoma: position paper from the International Society of Geriatric Oncology. Issue 6 (June 2018) Authors: Kanesvaran, Ravindran; Saux, Olivia Le; Motzer, Robert; Choueiri, Toni K; Scotté, Florian; Bellmunt, Joaquim; Launay-Vacher, Vincent Journal: Lancet oncology Issue: Volume 19:Issue 6(2018) Page Start: e317 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Fatigue in patients with advanced renal cell carcinoma receiving sunitinib on an intermittent versus continuous dosing schedule in a randomized phase II trial. (10th July 2014) Authors: Cella, David; Jensen, Sally E.; Hahn, Elizabeth A.; Beaumont, Jennifer L.; Korytowsky, Beata; Bhattacharyya, Helen; Motzer, Robert Journal: Cancer medicine Issue: Volume 3:Number 5(2014:Oct.) Page Start: 1353 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study. Issue 6 (June 2022) Authors: Motzer, Robert; Porta, Camillo; Alekseev, Boris; Rha, Sun Young; Choueiri, Toni K; Mendez-Vidal, Maria Jose; Hong, Sung-Hoo; Kapoor, Anil; Goh, Jeffrey C; Eto, Masatoshi; Bennett, Lee; Wang, Jinyi; Pan, Jie Janice; Saretsky, Todd L; Perini, Rodolfo F; He, Cixin Steven; Mody, Kalgi; Cella, David Journal: Lancet oncology Issue: Volume 23:Issue 6(2022) Page Start: 768 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Issue 3 (March 2023) Authors: Choueiri, Toni K; Eto, Masatoshi; Motzer, Robert; De Giorgi, Ugo; Buchler, Tomas; Basappa, Naveen S; Méndez-Vidal, María José; Tjulandin, Sergei; Hoon Park, Se; Melichar, Bohuslav; Hutson, Thomas; Alemany, Carlos; McGregor, Bradley; Powles, Thomas; Grünwald, Viktor; Alekseev, Boris; Rha, Sun Youn... Journal: Lancet oncology Issue: Volume 24:Issue 3(2023) Page Start: 228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗